Advanced Search

The Cost of Lung Cancer Management in France from the Payor's Perspective

Contents:

Author Info

  • Alain Vergnenegre

    (Service de l'information Medicale et de l'Evaluation, Service de Pneumologie, Hopital Cluzeau Limoges, Limoges, France)

  • Laurent Molinier

    (Laboratoire de Sante Publique et d'Epidemiologie, Inserm U558, Faculte de Medecine, Toulouse, France)

  • Christophe Combescure

    (Institut Universitaire de recherche clinique, Faculte de Medecine de Montpellier, Montpellier, France)

  • Jean-Pierre Daures

    (Institut Universitaire de recherche clinique, Faculte de Medecine de Montpellier, Montpellier, France)

  • Bruno Housset

    (Service de Pneumologie, Centre hospitalier Intercommunal, Creteil, France)

  • Christos Chouaid

    (Service de Pneumologie, Hopital Saint Antoine, Paris, France)

Registered author(s):

    Abstract

    Background: We assessed the average management cost per case of lung cancer in France according to the histological type and stage at diagnosis, together with the cost of each component of different treatment strategies. Methods: The sample was drawn from public and private hospitals that were treating large numbers of patients. The study covered the period from 1 July 1998 to 30 June 1999 and was based on medical chart review. A Markov model with six decision trees (two for small cell lung cancer [SCLC] and four for non-small cell lung cancer [NSCLC]) was used for the cost analysis. Treatment was broken down into first-line and second-line strategies, surveillance, and terminal care (TC). Results: The average management costs were _22_006 (_10_631-36_296) for 1 year and _25_643 (_10_631-41_191) for 2 years. The 2-year average costs were _22_420 for disseminated SCLC and _27_098 for localized SCLC. The costs of NSCLC ranged from _19_543 for nonsurgical stages to _30_024 for surgical stages and _24_383 for stage IV. The weight of the different components of each strategy differed markedly according to the diagnostic subgroup: the cost of diagnosis ranged from 7.4% to 14% of total management costs, and that of TC from 11.5% to 31.1%. The principal cost component was first-line chemotherapy (32-58.5%). Sensitivity analyses showed that, whatever the type of lung cancer, the percentage of actively treated patients was the main cost determinant. TC and chemotherapeutic lines also had important economic implications. Conclusion: The model developed here enables the component costs of different lung cancer management strategies in France to be assessed and the economic consequences of new treatment modalities to be predicted.

    Download Info

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
    File URL: http://diseasemanagement.adisonline.com/pt/re/dmo/pdfhandler.00115677-200614010-00007.pdf
    Download Restriction: Pay per view
    File URL: http://diseasemanagement.adisonline.com/pt/re/dmo/fulltext.00115677-200614010-00007.htm
    Download Restriction: Pay per view

    As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

    Bibliographic Info

    Article provided by Wolters Kluwer Health | Adis in its journal Disease Management & Health Outcomes.

    Volume (Year): 14 (2006)
    Issue (Month): 1 ()
    Pages: 55-67
    Download reference. The following formats are available: HTML (with abstract), plain text (with abstract), BibTeX, RIS (EndNote, RefMan, ProCite), ReDIF
    Handle: RePEc:wkh:dmhout:v:14:y:2006:i:1:p:55-67

    Contact details of provider:
    Web page: http://diseasemanagement.adisonline.com/

    For corrections or technical questions regarding this item, or to correct its listing, contact: (Dave Dustin).

    Related research

    Keywords: Cost-analysis; Lung-cancer; Lung-cancer; Markov-model; Non-small-cell-lung-cancer; Small-cell-lung-cancer;

    Find related papers by JEL classification:

    References

    No references listed on IDEAS
    You can help add them by filling out this form.

    Citations

    Lists

    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

    Statistics

    Access and download statistics

    Corrections

    When requesting a correction, please mention this item's handle: RePEc:wkh:dmhout:v:14:y:2006:i:1:p:55-67

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.